Literature DB >> 29601972

Complexation of Chol-DsiRNA in place of Chol-siRNA greatly increases the duration of mRNA suppression by polyplexes of PLL(30)-PEG(5K) in primary murine syngeneic breast tumors after i.v. administration.

Vishakha V Ambardekar1, Rajesh R Wakaskar2, Zhen Ye3, Stephen M Curran3, Timothy R McGuire4, Don W Coulter5, Rakesh K Singh6, Joseph A Vetro7.   

Abstract

RNA interference has tremendous potential for n class="Chemical">pan class="Disease">canpan>cerpan>> therapy but is limited by the insufficient potency of RNAi molecules after i.v. administration. We previously found that complexation with pan>n class="Chemical">PLL(30)-pan class="Chemical">PEG(5K) greatly increases the potency of 3'-cholesterol-modified siRNA [Chol-siRNA] in primary murine syngeneic 4T1 breast tumors after i.v. administration but mRNA suppression decreases 24 h after the final dose. We hypothesized that complexation of cholesterol-modified Dicer-substrate siRNA (Chol-DsiRNA) in place of Chol-siRNA can increase the potency and duration of suppression by polyplexes of PLL(30)-PEG(5K) in solid tumors. We found that replacing Chol-siRNA with Chol-DsiRNA increased polyplex loading and nuclease protection, suppressed stably expressed luciferase to the same extent in primary murine 4T1-Luc breast tumors under the current dosage regimen, but maintained suppression ~72 h after the final dose. The kinetics of suppression in 4T1-Luc over 72 h, however, were similar between DsiLuc and siLuc after electroporation and between polyplexes of Chol-DsiLuc and Chol-siLuc after transfection, suggesting that Chol-DsiRNA polyplexes increase the duration of mRNA suppression through differences in polyplex activities in vivo. Thus, replacing Chol-siRNA with Chol-DsiRNA may significantly increase the duration of mRNA suppression by polyplexes of PLL(30)-PEG(5K) and possibly other PEGylated polycationic polymers in primary tumors and metastases after i.v. administration.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chol-DsiRNA polymer micelles; Chol-DsiRNA polyplexes; Chol-siRNA polymer micelles; Chol-siRNA polyplexes; Drug delivery; DsiRNA; RNA interference

Mesh:

Substances:

Year:  2018        PMID: 29601972      PMCID: PMC5927825          DOI: 10.1016/j.ijpharm.2018.03.045

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  19 in total

1.  Kinetic analysis and modeling of firefly luciferase as a quantitative reporter gene in live mammalian cells.

Authors:  Jolene M Ignowski; David V Schaffer
Journal:  Biotechnol Bioeng       Date:  2004-06-30       Impact factor: 4.530

Review 2.  Strategies for silencing human disease using RNA interference.

Authors:  Daniel H Kim; John J Rossi
Journal:  Nat Rev Genet       Date:  2007-03       Impact factor: 53.242

Review 3.  Cellular delivery in vivo of siRNA-based therapeutics.

Authors:  A Aigner
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

4.  Hydrophobic interactions between polymeric carrier and palmitic acid-conjugated siRNA improve PEGylated polyplex stability and enhance in vivo pharmacokinetics and tumor gene silencing.

Authors:  Samantha M Sarett; Thomas A Werfel; Irene Chandra; Meredith A Jackson; Taylor E Kavanaugh; Madison E Hattaway; Todd D Giorgio; Craig L Duvall
Journal:  Biomaterials       Date:  2016-04-21       Impact factor: 12.479

5.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

Authors:  David V Morrissey; Jennifer A Lockridge; Lucinda Shaw; Karin Blanchard; Kristi Jensen; Wendy Breen; Kimberly Hartsough; Lynn Machemer; Susan Radka; Vasant Jadhav; Narendra Vaish; Shawn Zinnen; Chandra Vargeese; Keith Bowman; Chris S Shaffer; Lloyd B Jeffs; Adam Judge; Ian MacLachlan; Barry Polisky
Journal:  Nat Biotechnol       Date:  2005-07-24       Impact factor: 54.908

6.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

7.  Actively-targeted polyion complex micelles stabilized by cholesterol and disulfide cross-linking for systemic delivery of siRNA to solid tumors.

Authors:  Yusuke Oe; R James Christie; Mitsuru Naito; Stewart A Low; Shigeto Fukushima; Kazuko Toh; Yutaka Miura; Yu Matsumoto; Nobuhiro Nishiyama; Kanjiro Miyata; Kazunori Kataoka
Journal:  Biomaterials       Date:  2014-06-13       Impact factor: 12.479

8.  The efficacy of nuclease-resistant Chol-siRNA in primary breast tumors following complexation with PLL-PEG(5K).

Authors:  Vishakha V Ambardekar; Rajesh R Wakaskar; Bhawna Sharma; Joy Bowman; Willy Vayaboury; Rakesh K Singh; Joseph A Vetro
Journal:  Biomaterials       Date:  2013-04-01       Impact factor: 12.479

9.  In vivo bioluminescent imaging of mammary tumors using IVIS spectrum.

Authors:  Ed Lim; Kshitij D Modi; Jaebeom Kim
Journal:  J Vis Exp       Date:  2009-04-29       Impact factor: 1.355

Review 10.  Knocking down barriers: advances in siRNA delivery.

Authors:  Kathryn A Whitehead; Robert Langer; Daniel G Anderson
Journal:  Nat Rev Drug Discov       Date:  2009-02       Impact factor: 84.694

View more
  2 in total

1.  Preliminary preclinical study of Chol-DsiRNA polyplexes formed with PLL[30]-PEG[5K] for the RNAi-based therapy of breast cancer.

Authors:  Zhen Ye; Mai Mohamed Abdelmoaty; Vishakha V Ambardekar; Stephen M Curran; Shetty Ravi Dyavar; Lora L Arnold; Samuel M Cohen; Devendra Kumar; Yazen Alnouti; Don W Coulter; Rakesh K Singh; Joseph A Vetro
Journal:  Nanomedicine       Date:  2021-02-03       Impact factor: 5.307

2.  Direct Comparison of Chol-siRNA Polyplexes and Chol-DsiRNA Polyplexes Targeting STAT3 in a Syngeneic Murine Model of TNBC.

Authors:  Zhen Ye; Mai Mohamed Abdelmoaty; Stephen M Curran; Shetty Ravi Dyavar; Devendra Kumar; Yazen Alnouti; Don W Coulter; Anthony T Podany; Rakesh K Singh; Joseph A Vetro
Journal:  Noncoding RNA       Date:  2022-01-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.